Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial.

Research output: Contribution to journalArticle

Abstract

EURAMOS-1, an international randomized controlled trial, investigated maintenance therapy with pegylated interferon alfa-2b (IFN-α-2b) in patients whose osteosarcoma showed good histologic response (good response) to induction chemotherapy.

Details

Authors
  • Stefan S Bielack
  • Sigbjørn Smeland
  • Jeremy S Whelan
  • Neyssa Marina
  • Gordana Jovic
  • Jane M Hook
  • Mark D Krailo
  • Mark Gebhardt
  • Zsuzsanna Pápai
  • James Meyer
  • Helen Nadel
  • R Lor Randall
  • Claudia Deffenbaugh
  • Rajaram Nagarajan
  • Bernadette Brennan
  • G Douglas Letson
  • Lisa A Teot
  • Allen Goorin
  • Daniel Baumhoer
  • Leo Kager
  • Mathias Werner
  • Ching C Lau
  • Kirsten Sundby Hall
  • Hans Gelderblom
  • Paul Meyers
  • Richard Gorlick
  • Reinhard Windhager
  • Knut Helmke
  • Peter M Hoogerbrugge
  • Paula Schomberg
  • Per-Ulf Tunn
  • Thomas Kühne
  • Heribert Jürgens
  • Henk van den Berg
  • Tom Böhling
  • Susan Picton
  • Marleen Renard
  • Peter Reichardt
  • Joachim Gerss
  • Trude Butterfass-Bahloul
  • Carol Morris
  • Pancras C W Hogendoorn
  • Beatrice Seddon
  • Gabriele Calaminus
  • Maria Michelagnoli
  • Catharina Dhooge
  • Matthew R Sydes
  • Mark Bernstein
Organisations
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Cancer and Oncology
Original languageEnglish
Pages (from-to)2279-U92
JournalJournal of Clinical Oncology
Volume33
Issue number20
Publication statusPublished - 2015
Publication categoryResearch
Peer-reviewedYes

Total downloads

No data available